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Abstract
The development of molecular signatures for the prediction of time-to-event outcomes is a methodologically challenging
task in bioinformatics and biostatistics. Although there are numerous approaches for the derivation of marker combinations
and their evaluation, the underlying methodology often suffers from the problem that different optimization criteria are
mixed during the feature selection, estimation and evaluation steps. This might result in marker combinations that are
suboptimal regarding the evaluation criterion of interest. To address this issue, we propose a unified framework to derive
and evaluate biomarker combinations. Our approach is based on the concordance index for time-to-event data, which is a
non-parametric measure to quantify the discriminatory power of a prediction rule. Specifically, we propose a gradient
boosting algorithm that results in linear biomarker combinations that are optimal with respect to a smoothed version of the
concordance index. We investigate the performance of our algorithm in a large-scale simulation study and in two molecular
data sets for the prediction of survival in breast cancer patients. Our numerical results show that the new approach is not
only methodologically sound but can also lead to a higher discriminatory power than traditional approaches for the
derivation of gene signatures.
Citation: Mayr A, Schmid M (2014) Boosting the Concordance Index for Survival Data – A Unified Framework To Derive and Evaluate Biomarker
Combinations. PLoS ONE 9(1): e84483. doi:10.1371/journal.pone.0084483
Editor: Balraj Mittal, Sanjay Gandhi Medical Institute, India
Received July 19, 2013; Accepted November 14, 2013; Published January 6, 2014
Copyright:  2014 Mayr, Schmid. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work of Andreas Mayr and Matthias Schmid was supported by Deutsche Forschungsgemeinschaft (DFG) (www.dfg.de), grant SCHM 2966/1-1. The
authors further acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg within the funding
programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: andreas.mayr@fau.de
Introduction
Recent technological developments in the fields of genomics
and biomedical research have led to the discovery of large
numbers of gene signatures for the prediction of clinical survival
outcomes. In cancer research, for example, gene expression
signatures are nowadays used to predict the time to occurrence of
metastases [1,2] as well as the time to progression [3] and overall
patient survival [4,5]. While the importance of molecular data in
clinical and epidemiological research is expected to grow
considerably in the next years [6–8], the detection of clinically
useful gene signatures remains a challenging problem for
bioinformaticians and biostatisticians, especially when the out-
come is a survival time.
After normalization and data pre-processing, the development
of a new gene signature usually comprises three methodological
tasks:
Task 1: Select a subset of genes that is associated with the
clinical outcome.
Task 2: Derive a marker signature by finding the ‘‘optimal’’
combination of the selected genes.
Task 3: Evaluate the prediction accuracy of the optimal
combination using future or external data.
Task 1, the selection of a clinically relevant subset of genes, is
often addressed by calculating scores to rank the univariate
association between the survival outcome and each of the genes
[8,9]. In a subsequent step, the genes with the strongest
associations are selected to be included in the gene signature.
Task 2, the derivation of an optimal combination of the selected
genes, is usually fulfilled by forming linear combinations of gene
expression levels based on Cox regression. Due to multicollinearity
problems and the high dimensionality of molecular data, a direct
optimization of the Cox partial likelihood is often unfeasible [8].
Consequently, marker combinations are often derived by
combining coefficients of univariate Cox regression models [10],
or by applying regularized Cox regression techniques (such as the
Lasso [11,12] or ridge-penalized regression [13,14]).
Task 3, the evaluation of prediction accuracy, is considered to
be a challenging problem in survival analysis. This is because
traditional performance measures for continuous outcomes (such
as the mean squared error) are no longer applicable in the
presence of censoring. In the literature, several approaches to
address this problem exist (see, e.g., [15] for an overview). In this
article, we focus on the concordance index for time-to-event data (C-index
[16–18]), which has become a widely used measure of the
performance of biomarkers in survival studies [19–22]. Briefly
spoken, the C-index can be interpreted as the probability that a
patient with a small survival time is associated with a high value of
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a biomarker combination (and vice versa). Consequently, it
measures the concordance between the rankings of the survival
times and the biomarker values and therefore the ability of a
biomarker to discriminate between patients with small survival
times and patients with large survival times. This strategy is
especially helpful if the aim is to subdivide patients into groups
with good or poor prognosis (as applied in many articles in the
medical literature, e.g., [10]). By definition, the C-index has the
same scale as the classical area under the curve (AUC) in binary
classification: While prediction rules based on random guessing
yield C~0:5, a perfectly discriminating biomarker combination
leads to C~1.
Interestingly, the derivation of new gene signatures for survival
outcomes via Tasks 1–3 is often addressed by combining
completely different methodological approaches and estimation
techniques. For example, the estimation of biomarker combina-
tions is usually based on Cox regression and is hence carried out
via the optimization of a partial likelihood criterion. On the other
hand, the resulting combinations are often evaluated by using the
C-index [21,22] which has its roots in the receiver operating
characteristics (ROC) methodology. This methodological incon-
sistency is also problematic from a practical point of view, as the
marker combination that optimizes the partial log likelihood
criterion is not necessarily the one that optimizes the C-index. In
other words, if the C-index and therefore the discriminatory
power is the evaluation criterion of interest, it may be suboptimal
to use a likelihood-based criterion to optimize the marker
combination. This issue is, of course, not only problematic in
survival analysis but also in regression and classification. A
theoretical discussion on the differences between performance
measures for binary classification can, e.g., be found in [23].
To overcome the aforementioned inconsistencies, we propose a
unified framework for survival analysis that is based on the same
statistical methodology for gene selection (Task 1), derivation of an
optimal biomarker combination (Task 2) and the evaluation of a
new gene signature (Task 3). As will be demonstrated, all three
tasks can be addressed by using the concordance index for time-to-
event data as performance criterion. While the C-index has
already been proposed for gene selection (Task 1) and the
evaluation of prediction accuracy (Task 3) [9,15], the main
contribution of this article is a new estimation technique that
addresses the development of optimal combinations of genes (Task
2). To achieve this goal, we propose a method for finding gene
combinations that is based on the gradient boosting framework
[24]. As will be shown, it is possible to use boosting to derive
prediction-optimized gene combinations via direct optimization of
the C-index. Because this new approach allows for using the C-
index to address all three tasks, the proposed method leads to a
consistent framework for the derivation of gene signatures in




We first introduce some basic notation that will be used
throughout the article. Let T [ Rz be the survival time of interest
and X~(x1,:::,xp) [ R
p a vector of predictor variables. In
addition to the gene expression levels, X may contain the
measurements of some clinical predictor variables. Denote the
conditional survival function of T given X by
S(tjx)~P(TwtjX~x). The probability density and survival
functions of T are denoted by f (t) and S(t), respectively. Further
let Tcens [ R
z be a random censoring time and denote the
observed survival time by ~T : ~ min (T ,Tcens). The random
variable D : ~I(TƒTcens) indicates whether ~T is right-censored
(D~0) or not (D~1).







where b is an unknown vector of coefficients. We generally assume
that the estimation of b̂ is based on an i.i.d. learning sample
f(~TLi ,DLi ,X Li ), i~1, . . . ,ng. In case of the Cox regression model,
for example, g is related to T by the equation
S(tjx)~ exp ({L0(t): exp (g)) , ð2Þ
where L0(t) is the cumulative baseline hazard function. Because
there is a one-to-one relationship between g and the expected
survival time E(T jX ), the linear combination g can be used as a
biomarker to predict the survival of individual patients.
Concordance index
Our proposed framework to derive and evaluate biomarker
combinations is based on the concordance index (‘‘C-index’’) which is
a general discrimination measure for the evaluation of prediction
models [16,17]. It can be applied to continuous, ordinal and
dichotomous outcomes [25]. For time-to-event outcomes, the C-
index is defined as
C : ~P(gj1wgj2 jTj1vTj2 ) , ð3Þ
where Tj1 , Tj2 and gj1 , gj2 are the event times and the predicted
marker values, respectively, of two observations in an i.i.d. test
sample f( ~Tj ,Dj ,Xj),j~1, . . . ,Ng. By definition, the C-index for
survival data measures whether large values of g are associated
with short survival times T and vice versa. Moreover, it can be
shown that the C-index is equivalent to the area under the time-
dependent ROC curve, which is a measure of the discriminative
ability of g at each time point under consideration (see [26], p. 95
for a formal proof).
During the last decades, the C-index has gained enormous
popularity in biomedical research; for example, searching for the
terms ‘‘concordance index’’ and ‘‘c-index’’ in PubMed [27]
resulted in 1156 articles by the time of writing this article.
Generally, a value of C close to 1 indicates that the marker g is
close to a perfect discriminatory power, while a marker that does
not perform better than chance results in a value of 0.5. For
example, the famous Gail model [28] for the prediction of breast
cancer is estimated to yield a value of C~0:67 [29].
Being a flexible discrimination measure, the C-index is
especially useful for selecting and ranking genes from a pre-
processed set of high-dimensional gene expression data (Task 1
described in the Introduction). In other words, Task 1 can be
addressed by computing the C-index (and hence the marginal
discriminatory power) for each individual gene or biomarker,
where only those genes with the highest C-index are incorporated
into the yet-to-derive optimal combination (Task 2). Although
there exist various other ways to rank genes and select the most
influential ones, the C-index has been demonstrated to be
especially advantageous for this task [9].
Boosting the Concordance Index for Survival Data
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with j,k [ f1, . . . ,ng (‘‘Harrell’s C for survival data’’, [30]).
Generally, Ĉsurv is a consistent estimator of the C-index in
situations where no censoring is present. However, because pairs
of observations where the smaller observed survival time is
censored are ignored in formula (4), Ĉsurv is known to show a
notable upward bias in the presence of censoring. This bias tends
to be correlated with the censoring rate [15,30].
To overcome the censoring bias of Ĉsurv, Uno et al. [18]




















where ĜLn (t) denotes the Kaplan-Meier estimator of the
unconditional survival function of Tcens (estimated from the
learning data). In the following, we will assume that the censoring
times are independent of X . Under this assumption, ĈUno is a
consistent and asymptotically normal estimator of C (see [18], pp.
1113–1115). Consistency is ensured by applying inverse probabil-




2), which account for
the inverse probability that an observation in the test data is
censored [31]). Numerical studies suggest that ĈUno is remarkably
robust against violations of the random censoring assumption [32].
Apart from the estimators Ĉsurv and ĈUno, there exist various
other approaches to estimate the probability in (3) (see, e.g., [15]
for an overview). Most of these approaches are based on the
assumptions of a Cox proportional hazards model, so that they are
not valid in case these assumptions are violated. Because ĈUno is
model-free and because the consistency of ĈUno is guaranteed
even in situations where censoring rates are high (in contrast to the
estimator Ĉsurv), we will base our boosting method on ĈUno.
Boosting the concordance index
The core of our proposed framework to address Tasks 1 – 3 is
the derivation of a prediction-optimized linear combination of
genes that is optimal w.r.t. to the C-index for time-to-event data.
Our approach will be based on a component-wise gradient
boosting algorithm [24] that uses the C-index as optimization
criterion.
Gradient boosting algorithms [33] are generally based on a loss
function r(T ,g) that is assumed to be differentiable with respect to




min T ,X r(T ,g(X ))½  ð6Þ
by using gradient descent techniques. As the theoretical mean in
(6) is usually unknown in practice, gradient boosting algorithms





When considering the C-index for survival data, the aim is to
determine the optimal predictor g that maximizes the concor-
dance measure C~P(gi wg

k jTivTk) – which is essentially the
solution to Task 2. Hence a natural choice for the empirical risk















  : ð7Þ
Setting R~{ĈUno(T ,g), however, is unfeasible because
ĈUno(T ,g) is not differentiable with respect to gi and can
therefore not be used in a gradient boosting algorithm. To solve
this problem, we follow the approach of Ma and Huang [34] and
approximate the indicator function in (7) by the sigmoid function
K(u)~1=(1z exp ({u=s)). Here, s is a tuning parameter that
controls the smoothness of the approximation (details on the
choice of s will be given in the Numerical Results section).
Replacing the indicator function in (7) by its smoothed version
results in the smoothed empirical risk function























  : ð9Þ
By definition, the smoothed empirical risk {Ĉsmooth(T ,g) is













s 1 z exp
ĝk{ĝi
s
   : ð10Þ
In the proposed gradient boosting algorithm, the derivative in
(10) is iteratively fitted to a set of base-learners. Typically, an
individual base-learner (simple regression tool, e.g., a tree or a
simple linear model) is specified for each marker. To ensure that
the estimate of the optimal predictor g is a linear combination of
the components of X , we will apply simple linear models as base-
learners (cf. [35]). In other words, each base-learner is a simple
linear model with one component of X as input variable.
Consequently, there are p base-learners, which will be denoted
by bl , l~1, . . . ,p. Each base-learner refers to one component of X
and therefore to one marker (or gene).
The component-wise gradient boosting algorithm for the
optimization of the smoothed C-index is then given as follows:
1. Initialize the estimate of the marker combination ĝ½0 with
offset values. For example, set ĝ½0~0, leading to b̂
½0
l ~0 for all
components l~1, . . . ,p. Choose a sufficiently large maximum
number of iterations mstop and set the iteration counter m to 1.
Boosting the Concordance Index for Survival Data
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2. Compute the negative gradient vector by using formula (10)













3. Fit the negative gradient vector U ½m separately to each of the
components of X via the base-learners bl(:):
U ½m ?fitted by b̂½ml (xl) for l~1,:::,p:
4. Select the component l that best fits the negative gradient
vector according to the least squares criterion, i.e., select the












5. Update the marker combination ĝ for this component:
ĝ½m/ĝ½m{1zsl:b̂½ml (xl ) ,
where sl is a small step length (0vsl%1). For example, if
sl~0:1, only 10% of the fit of the base-learner is added to the
current marker. This procedure shrinks the effect estimates
towards zero, effectively increasing the numerical stability of
the update step [23,25].
As only the base learner b̂l was selected, only the effect of







l (xl )) while all






6. Stop if m~mstop. Else increase m by one and go back to step
(2).
By construction, the proposed boosting algorithm automatically
estimates the optimal linear biomarker combination that maxi-
mizes the smoothed C-index. The principle behind the proposed
algorithm is to minimize the empirical risk R~{Ĉsmooth(T ,g) by
using gradient descent in function space, where the function space
is spanned by the base-learners bl , l~1,:::,p. In other words, the
algorithm iteratively descents the empirical risk by updating ĝ½m
via the best fitting base-learner. Because the base-learners are
simple linear models (each containing only one possible biomarker
as predictor variable) and because the update in step (5) of the
algorithm is additive, the final solution ĝ½mstop effectively becomes a
linear combination of these markers.
The two main tuning parameters of gradient boosting
algorithms are the stopping iteration mstop and the step length
sl. In the literature it has been argued that the choice of the step
length is of minor importance for the performance of boosting
algorithms [36]. Generally, a larger step length leads to faster
convergence of the algorithm. However, it also increases the risk of
overshooting near the minimum of R. In the following sections we
will use a fixed step-length of sl~0:1, which is a common
recommendation in the literature on gradient boosting and which
is also the default value in the R package mboost [37].
The stopping iteration mstop is considered to be the most
important tuning parameter of boosting algorithms [38]. The
optimal value of mstop is usually determined by using cross-
validation techniques [24]. Small values of mstop reduce the
complexity of the resulting linear combination ĝ½mstop and avoid
overfitting via shrinking the effect estimates. In case of boosting the
C-index, however, overfitting is less problematic as the predictive
performance of g is not related to the actual size of the coefficients
but to the concordance of the rankings between marker values and
the observed survival times. As a result, the stopping iteration
mstop in this specific case is less relevant and can be also specified
by a fixed large value (e.g., mstop~50000).
Regarding the boosting algorithm for the smoothed C-index, an
additional tuning parameter is given by the smoothing parameter
s. While too large values of s will lead to a poor approximation of
the indicator functions in (7), too small values of s might overfit the
data (and might therefore result in a decreased prediction
accuracy). Details on how to best choose the value of s will be
given in the Numerical Results section.
The boosting algorithm presented above is implemented in the
add-on software package mboost of the open source statistical
programming environment R [39]. The specification of the new
Cindex() family and a short description of how to apply the
algorithm in practice are given in Text S1.
Evaluation
After having applied the C-index to select the most influential
genes (Task 1), and after having used the proposed boosting
algorithm to combine the selected genes (Task 2), a final challenge
is to evaluate the prediction accuracy of the resulting gene
combination (Task 3). Since the C-index was used for Tasks 1 and
2, it is also a natural criterion to evaluate the derived marker
combination in Task 3. As argued before, it is advantageous from
both a methodological perspective as well as from a practical one
to use the same criterion for estimation and evaluation of a
biomarker combination.
To avoid over-optimistic estimates of prediction accuracy, it is
crucial to use different observations for the optimization and
evaluation of the marker signature [25,40]. This can be achieved
either by using two completely different data sets (external evaluation)
or by splitting one data-set into a learning sample f(~TLi ,DLi ,X Li ),
i~1, . . . ,ng and a test sample f( ~Tj ,Dj ,Xj), j~1, . . . ,Ng. The
learning sample is used to optimize the marker combination while
the ‘‘external’’ test sample serves only for evaluation purposes. A
more elaborate strategy is subsampling (such as five-fold or ten-fold
cross-validation), which is based on multiple random splits of the
data. In our numerical analysis, we will use subsampling
techniques in combination with stratification to divide the
underlying data sets into learning and test samples (for details,
see the next section).
When it comes to the C-index, two additional points have to be
taken into consideration: First, as the task is to obtain the most
precise estimation for the discriminatory power, it is no longer
necessary to use the smoothed version Ĉsmooth (which was
included for numerical reasons in the boosting algorithm) for
evaluation. Consequently, we propose to apply the original
estimator ĈUno for evaluating biomarker combinations in Task
3. Second, when applying the estimator ĈUno to the observations
in a test sample, a natural question is how to calculate the Kaplan-
Meier estimator ĜLn (t) of the unconditional survival function of
Tcens. In principle, there are three possibilities for the calculation
of ĜLn (t): The Kaplan-Meier estimator can be computed from
Boosting the Concordance Index for Survival Data
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either the test or from the training data, or, alternatively, from the
combined data set containing all observations in the learning and
test samples. Following the principle that all estimation steps
should be carried out prior to Task 3, we will base computation of
the Kaplan-Meier estimator on the learning data.
Numerical results
Simulation study. We first investigated the performance of
our approach based on simulated data. The aim of our simulation
study was:
(i) To analyze if the proposed framework is able to select a
small amount of informative markers from a much larger set
of candidate variables.
(ii) To check if gradient boosting is able to derive the optimal
combination g of the selected markers, and to compare its
performance to competing Cox-based estimation schemes.
(iii) To investigate the effect of the smoothing parameter s that
controls the smoothness inside the sigmoid function, as well
as potential effects of the sample size and the censoring rate
on the performance of our approach.
The simulated survival times are generated via a log-logistic
distribution for accelerated failure time (AFT) models [41]. They
are based on the model equation log (T)~mzwW , where T is
the survival time, m and w are location and scale parameters, and
W is a noise variable, following a standard logistic distribution. As
a result, the density function for realizations ti can be written as
fdens(tijmi,wi)~
exp (ti{mi)=wið Þ
wi 1z exp (ti{mi)=wið Þð Þ2
ð11Þ
with (T)~m and Var(T)~
p2
3w2
. The p~1000 possible
markers X1,::::,X1000 were drawn from a multivariate normal
distribution with pairwise correlation (r~0:5). The true underlying
combinations of the predictors were given by
mi~gm~1:5z1:5x1zx2{x3{1:5x4 ,
log (wi)~gw~{1z2x1{2x2zx3{x4 :
Note that only four out of 1000 possible markers have an actual
effect on the survival time. Furthermore, those four markers do not
only contribute to the location parameter m but also to the scale
parameter w (cf. [42]) – a setting where standard survival analysis
clearly becomes problematic. Additionally to the survival times T ,
we generated an independent sample of censoring times Tcens and
defined the observed survival time by ~T : ~ min (T ,Tcens) leading
to independent censoring of 50% of the observations.
In order to answer the above questions, we investigated the
performance of our framework in all three tasks that are necessary
to develop new gene signatures in practice (Tasks 1–3 described in
the Introduction). To avoid over-optimism and biased results, we
simulated separate data sets for the different tasks. In B~100
simulation runs, we first simulated a data set
f( ~Ti,Di,Xi), i~1, . . . ,1000g with 1000 observations to pre-select
the most influential predictors based on the C-index (Task 1). The
optimal combination g of those predictors was later estimated





i ), i~1, . . . ,ng of size n. For the final external
evaluation of the prediction accuracy (Task 3) we simulated a
separate test data set f( ~Tj ,Dj ,Xj), j~1, . . . ,Ng with N~1000.
For Task 1, we first pre-selected a subset of p predictors from
the p~1000 available markers. We ranked the predictors based on
their individual values of ĈUno and included only the
p~f5,10,30g best-performing markers in the boosting algorithm.
The results suggest that the C-index is clearly able to identify
markers that are truly related to the outcome: Although all
predictors had a relatively high pairwise correlation (r~0:5), the
four informative markers had a selection probability of 98.5% for
p~5 (99% for p~10 and 99.5% for p~30).
To find the optimal combination g of the pre-selected markers
(Task 2), we applied the proposed boosting approach on training
samples with size n~100. The resulting coefficients for p~5 and
smoothing parameter s~0:1 are presented in Figure 1. The
boosting algorithm seems to be able to derive the optimal
combination of the pre-selected markers, as the structure displayed
by the coefficients is essentially the same as the one of the
underlying true combination gm. The discriminatory power of the
resulting biomarker does not depend on the absolute size of the
coefficients: As the C-index is based solely on the concordance
between biomarker and survival time, what matters in practice is
the relative size of the coefficients. As can be seen from Figure 1, the
estimated positive effect for x1 is larger than the one for x2. On the
other hand, the negative effect of x4 is correctly estimated to be
more pronounced than the the one of x3. The coefficient of the
falsely selected marker is on average close to zero.
In a third step, we evaluated the performance of the resulting
optimized marker combinations (Task 3) on separate test samples.
The resulting estimates ĈUno for different simulation settings are
presented in Table 1. The highest discriminatory power (median
ĈUno~0:763, range = 0.559–0.819) can be observed for p
~5,
which is closest to the true number of informative markers. We
compared the performance of our proposed algorithm to
penalized Cox regression approaches such as Cox-Lasso [11,12]
and Cox regression with ridge-penalization [13,14] – see Figure 2.
The proposed boosting approach clearly outperforms the com-
peting estimation schemes, supporting our view that applying
traditional Cox regression might be suboptimal if the discrimina-
tory power is the performance criterion of interest. We addition-
ally computed the optimal C-index resulting from the true marker
combination gm with known coefficients. The values of the true C-
index on the test samples are on average only slightly better than
the ones of boosting the concordance index (median ĈUno~0:778
– see Table 1).
To evaluate the possible effects of different sample sizes and
censoring rates we modified the mean censoring time leading to
approximate censoring rates of 30% and 70% and generated
training samples of size n~f50,200,500g. Results are included in
Table 1. As expected, the C-index resulting from our framework
increases as censoring rates become small (median ĈUno~0:820,
range = 0.736–0.858) and decreases in settings with a large
proportion of censored observations (median ĈUno~0:668, range
= 0.421–0.776). However, the same effect can be observed for the
true C-index resulting from the true marker combination gm (30%
censoring ĈUno~0:830, 70% censoring ĈUno~0:690). For larger
training samples, the variance of the coefficient estimates decreases
(see Figure 1). As a result, the discriminatory power resulting from
our boosting algorithm improves (for n~500, median
ĈUno~0:778, range = 0.614–0.818) and gets nearly as good as
Boosting the Concordance Index for Survival Data
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the true C-index (ĈUno~0:781). This finding further confirms the
ability of our approach to find the most optimal marker
combination possible – see Figure 2. Note that also the true C-
index differs slightly between the different sample sizes, as the
training sample enters in ĈUno via the Kaplan-Meier estimator
ĜLn (t).
To investigate the effect of the smoothing parameter inside the
sigmoid function, we additionally applied our boosting procedure
for every simulation setting with different values of s. The
resulting estimates ĈUno are presented in Table 2. Compared to
the effects of the sample size or the number of pre-selected markers
p, the smoothing parameter s only seems to have a minor effect
on the performance of our algorithm. In light of these empirical
results, we recommend to apply a fixed small value (e.g., s~0:1,
which is also the default value in the Cindex() family for the
mboost package [37] – see Text S1).
For both approaches to fit penalized Cox regression (Cox lasso,
Cox ridge), we applied the R add-on package penalized [43]. In
order to evaluate ĈUno, we used the UnoC() function implemented
in the survAUC package [44].
Applications to predict the time to distant metastases
In the next step, we further analyzed the performance of our
gradient boosting algorithm in two applications to estimate and
evaluate the optimal combination of pre-selected biomarkers. All
markers are used to predict the time to distant metastases in breast
cancer patients. As in the simulation study, we compared the
results of our proposed algorithm to Cox regression with lasso and
ridge penalization. Additionally, we considered four competing
Figure 1. Coefficient estimates for p~5 pre-selected markers obtained from 100 simulation runs. The marker combinations were
optimized via gradient boosting based on training samples of size n~100 (left) and n~500 (right). Boxplots represent the empirical distribution of
the resulting coefficients. Only markers X1 to X4 had an actual effect on the survival time.
doi:10.1371/journal.pone.0084483.g001
Table 1. Results of the simulation study.
setting method
n p cens: C-index boosting Cox lasso Cox ridge true C-index
100 5 50% 0.764 (0.04) 0.731 (0.06) 0.739 (0.04) 0.779
100 10 50% 0.746 (0.06) 0.709 (0.08) 0.707 (0.06) 0.779
100 30 50% 0.689 (0.07) 0.673 (0.11) 0.637 (0.07) 0.779
100 5 30% 0.820 (0.02) 0.774 (0.04) 0.724 (0.04) 0.830
100 5 70% 0.668 (0.10) 0.628 (0.10) 0.593 (0.11) 0.690
50 5 50% 0.741 (0.07) 0.662 (0.18) 0.722 (0.09) 0.772
200 5 50% 0.774 (0.02) 0.748 (0.04) 0.752 (0.04) 0.782
500 5 50% 0.778 (0.03) 0.759 (0.03) 0.760 (0.02) 0.781
Comparison of the discriminatory power resulting from boosting the C-index and competing approaches. Numbers refer to the median value and interquartile range (in
parentheses) of the final ĈUno on 100 simulation runs. The true C-index refers to the discriminatory power resulting from the true combination of predictors with known
coefficients. The amount of pre-selected genes is denoted as p , n is the size of the training samples and cens. refers to the censoring rate.
doi:10.1371/journal.pone.0084483.t001
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boosting approaches for survival analysis, which do not directly
optimize the C-index. The first is classical Cox regression,
estimated via gradient boosting, while the other three are
parametric accelerated failure-time (AFT) models assuming a
Weibull, log-normal or log-logistic distribution [45,46]. For all
boosting approaches (Weibull AFT boosting, loglog-AFT boosting
and Cox boosting) we used the corresponding pre-implemented
functions of the mboost package. To ensure comparability, we
used the same linear base-learners as described above for all
boosting approaches.
To ensure that the combined predictor did not only work on the
data it was derived from but also on ‘‘external’’ validation data, we
carried out a subsampling procedure for both data sets to generate
B~100 different learning samples f(~TLi ,DLi ,X Li ), i~1, . . . ,ng and
test samples f( ~Tj ,Dj ,Xj),j~1, . . . ,Ng, respectively. Consequently,
we randomly split the corresponding data sets to use 2=3 of the
observations as learning sample in order to optimize the biomarker
combination ĝ. To ensure an equal distribution of patients with
and without an observed development of distant metastases we
applied stratified sampling. Correspondingly, the 1=3 of the
observations not included in the learning sample were used to
evaluate the resulting predictions via the C-index. As a result, for
every data set and every method we computed 100 different
combinations g and 100 corresponding values of ĈUno.
Breast cancer data by Desmedt et al.
Desmedt et al. [1] collected a data set of 196 node-negative
breast cancer patients to validate a 76-gene expression signature
developed by Wang et al. [10]. The signature, which is based on
Affymetrix microarrays, was developed separately for estrogen-
receptor (ER) positive patients (60 genes) and ER-negative patients
(16 genes). In addition to the expression levels of the 76 genes, four
clinical predictor variables were considered (tumor size, estrogen
receptor (ER) status, grade of the tumor and patient age). The data
are publicly available on GEO (http://www.ncbi.nlm.nih.gov/
geo, accession number GSE 7390).
Similar to Wang et al. [10], we used the time from diagnosis to
distant metastases as primary outcome and considered the 76
genes together with the four clinical predictors. Observed
metastasis-free survival ranged from 125 days to 3652 days, with
79.08% of the survival times being censored.
The main results of our analysis are presented in Figure 3. As
expected, the unified framework to estimate and evaluate the
optimal marker signature based on the C-index is not only
methodologically more consistent than the Cox and AFT
approaches, but also leads to to marker signatures that show a
higher discriminatory power on external or future data (median
ĈUno~0:736, range = 0.467–0.854). As discussed in the
methodological section, it is crucial to evaluate the discriminatory
power on external data: the estimated C-index on the training
sample was more than 35% higher (median ĈUno~0:986) and
hence extremely over-optimistic [25,40].
Considering the interpretation of the resulting coefficient
estimates for the clinical predictors, it is crucial to note that
boosting methods for the C-index and the AFT models yield
biomarker combinations g where larger values indicate longer
predicted survival times. On the other hand, classical Cox
regression models rely on the hazard; higher values are hence
associated with smaller survival times. If this is taken into account,
results from the different approaches were in fact very similar.
Both age of the patients and size of the tumor had a negative effect
on the time to recurrence for all seven approaches. The same
holds true for the tumor grade poor differentiation which resulted in a
negative effect compared to good differentiation and intermediate
differentiation. A positive ER status, on the other hand, was
associated with a larger metastasis-free survival in all approaches.
Regarding the coefficients of the 76 genes, results from our
approach to boost the C-index were highly correlated to the ones
Figure 2. Simulation results for the discriminatory power obtained via the proposed C-index boosting approach and competing
Cox-based estimation schemes. The marker combinations were optimized via the different approaches based on training samples of size n~100
(left) and n~500 (right). Boxplots represent the empirical distribution of the resulting ĈUno on corresponding test samples. The dotted line
corresponds to the discriminatory power resulting from the true combination of predictors with known coefficients.
doi:10.1371/journal.pone.0084483.g002
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of the other four boosting approaches (which rely on the same
base-learners) – absolute correlation coefficients computed from
the 100 subsamples ranged from 0.77 to 0.99. Also coefficients
resulting from the popular ridge-penalized Cox regression were
highly correlated with the ones from our approach – absolute
correlation coefficients ranged from 0.47 to 0.84.
Breast cancer data by van de Vijver et al.
The second data set consists of 144 lymph node positive breast
cancer patients that was collected by the Netherlands Cancer
Institute [2]. The data set, which is publicly available as part of the
R add-on package penalized [43], was used by van de Vijver et al.
[2] to validate a 70-gene signature for metastasis-free survival after
surgery developed by van’t Veer et al. [47]. In addition to the
expression levels of the 70 genes, the data set contains five clinical
predictor variables (tumor diameter, number of affected lymph
nodes, ER status, grade of the tumor and patient age). Observed
metastasis-free survival times ranged from 0:055 months to 17:660
months, with 67% of the survival times being censored.
Resulting values of the C-index of the new approach and the six
considered competitors are presented in Figure 3. The improve-
ment from applying the proposed unified framework compared to
boosting the Cox proportional hazard model or applying ridge-
penalized Cox regression was much less pronounced than in the
previous data set. However, on average, boosting the C-index still
led to the best combination of markers regarding the discrimina-
tory power (median ĈUno~0:662, range = 0.257–0.836).
Interestingly, as in the previous data set, the lasso penalized Cox
regression was clearly outperformed by the ridge-penalized
competitor (which has been suggested for this specific data set
Table 2. Simulation results for different values of the smoothing parameter.
setting smoothing parameter
n p cens: s~0:5 s~0:25 s~0:1 s~0:075 s~0:05
100 5 50% 0.738 (0.06) 0.757 (0.05) 0.764 (0.04) 0.763 (0.04) 0.762 (0.04)
100 10 50% 0.728 (0.06) 0.744 (0.06) 0.746 (0.06) 0.746 (0.06) 0.741 (0.05)
100 30 50% 0.700 (0.06) 0.702 (0.07) 0.689 (0.07) 0.683 (0.07) 0.666 (0.07)
100 5 30% 0.802 (0.03) 0.815 (0.02) 0.820 (0.02) 0.821 (0.02) 0.822 (0.02)
100 5 70% 0.665 (0.10) 0.667 (0.10) 0.668 (0.10) 0.665 (0.10) 0.661 (0.10)
50 5 50% 0.719 (0.07) 0.737 (0.07) 0.741 (0.07) 0.740 (0.06) 0.725 (0.06)
200 5 50% 0.743 (0.05) 0.768 (0.03) 0.774 (0.02) 0.775 (0.02) 0.778 (0.02)
500 5 50% 0.723 (0.05) 0.769 (0.02) 0.778 (0.03) 0.779 (0.03) 0.781 (0.03)
Comparison of the discriminatory power resulting from the gradient boosting approach when applying different values of the smoothing parameter s. Numbers refer
to to the median value and interquartile range (in parentheses) of the final ĈUno on 100 simulation runs. The amount of pre-selected genes is denoted as p
 , n is the size
of the training samples and cens. refers to the censoring rate. We recommend to use the value s~0:1, which is also the default value of the new Cindex family for the R
add-on package mboost.
doi:10.1371/journal.pone.0084483.t002
Figure 3. Comparing the discriminatory power of biomarker combinations to predict the time to distant metastases resulting from
the proposed C-index boosting approach with competing estimation schemes. The plot on the left refers to the Desmedt et al. data,
whereas the plot on the right presents results from the van de Vijver et al. data. All biomarker combinations were optimized via the corresponding
algorithms based on the same 100 learning samples. Boxplots represent the empirical distribution of the resulting ĈUno on corresponding test
samples. The dotted line corresponds to the median C-index resulting from the new approach.
doi:10.1371/journal.pone.0084483.g003
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by van Houwelingen et al. [48]). Furthermore, the ridge-penalized
approach performed at least as good as the considered boosting
approaches (except the new approach to boost the C-index). As in
the previous data set, we again additionally evaluated the C-index
on the training sample in order to assess the resulting over-
optimism. As expected, the estimated C-index on the training
sample was extremely biased (median ĈUno~0:973).
The resulting coefficients for the clinical predictors were again
comparable for the seven different approaches. A positive ER
status was associated with a larger metastasis-free survival for all
seven approaches, the same also holds true for the age of the
patient. On the other hand, the size of the tumor, the number of
affected lymph nodes and a poor tumor grade resulted for all
approaches in a negative effect on the survival time. Regarding the
coefficients of the 79 genes, the highest correlation could again be
observed for the boosting algorithms: Absolute correlation
coefficients obtained from the 100 subsamples ranged from 0.64
to 0.95. Correlation between coefficients resulting from our
approach to boost the C-index and the ones from ridge-penalized
Cox regression was slightly lower, it ranged from 0.30 to 0.82.
Discussion
In this article we have proposed a framework for the
development of survival prediction rules that is based on the
concordance index for time-to-event data (C-index). As the C-
index is an easy-to-interpret measure of the accuracy of survival
predictions (based on clinical or molecular data), it has become an
important tool in medical decision making. Generally, the focus of
the C-index is on measuring the ‘‘discriminatory power’’ of a
prediction rule: It quantifies how well the rankings of the survival
times and the values of a biomarker (or marker combinations) in a
sample agree. In particular, the C-index is methodologically
different from measures that evaluate how well a prediction rule is
‘‘calibrated’’ (i.e., from measures that quantify ‘‘how closely the
predicted probabilities agree numerically with the actual out-
comes’’ [49]). Specifically, prediction rules that are well calibrated
do not necessarily have a high discriminatory power (and vice
versa).
While several authors have proposed the use of the C-index for
feature selection [9] and the evaluation of molecular signatures
[21,22], the main contribution of this paper is a new approach for
the derivation of marker combinations that is based directly on the C-
index. Consequently, when using the proposed method, it is no
longer necessary to rely on traditional methods such as Cox
regression – which focus on the derivation of well-calibrated
prediction rules instead of well-disciminating prediction rules and
may therefore be suboptimal when the optimization of the
discriminatory power is of main interest.
Conceptually, our approach is in direct line with recent articles
by Ma and Huang [34], Wang and Chang [50] and Schmid et al.
[51] who developed a set of algorithms for the optimization of
discrimination measures for binary outcomes (such as the area
under the curve (AUC) and the partial area under the curve and
(PAUC)). Because the C-index is in fact a summary measure of a
correspondingly defined AUC measure for time-to-event data
[26], our optimization technique relies on similar methodological
concepts, such as the application of boosting methods and the use
of smoothed indicator functions.
A possible future extension of our approach might be to include
the task of selecting the most influential genes in the proposed
boosting algorithm. While our simulation study and the breast-
cancer examples were based on the pre-selection of genes, the
proposed boosting method could also be applied directly to high-
dimensional molecular data, so that Tasks 1 and 2 are effectively
combined. This can be accomplished by optimizing the stopping
iteration so that only a (low-dimensional) subset of the candidate
genes is incorporated in the resulting marker combination (‘‘early
stopping’’, cf. [38]). Further research is warranted on the issues of
early stopping and automated feature selection in the case of
boosting the concordance index for survival data.
The results of our empirical analysis suggest that the new
approach is competitive with state-of-the-art methods for the
derivation of marker combinations. As demonstrated in the
Numerical Results section, the resulting marker combinations
are not only easy to compute and have a meaningful interpretation
but can also lead to a higher discriminatory power of the resulting
gene signatures.
Supporting Information
Text S1 This document provides technical details on
boosting the concordance index. It contains the implemen-
tation of the new Cindex() family and a short description of the
necessary R Code to apply the algorithm in practice.
(PDF)
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